MAYO CLINIC: $40.3M Department of Health and Human Services Federal Award
Summary
The NIH's $40.3M award to the Mayo Clinic for the All of Us Biobank supports precision medicine infrastructure, reinforcing the healthcare sector's long-term growth in biobanking and genomics. As a private entity, no direct public ticker exposure exists, but the contract signals sustained federal investment in large-scale biorepositories.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The contract is a multi-year renewal for the All of Us Biobank, a cornerstone of U.S. precision medicine efforts.
- 2.Mayo Clinic's private status means no direct ticker connection; investors should monitor supply chain beneficiaries in genomics and laboratory services.
- 3.The award reflects steady government spending on biopharma infrastructure, a secular growth trend.
Market Implications
For public companies, the indirect beneficiaries include laboratory equipment suppliers ($TMO, $DHR) and genomic sequencing firms ($ILMN, $PACB) that provide the tools for biospecimen processing and analysis. As the All of Us program scales sample collection and distribution, these vendors may see increased orders. However, the contract amount is modest relative to the revenues of these large-cap firms, limiting immediate price impact. The broader trend of federal investment in precision medicine is a positive structural driver for the healthcare sector.
Full Analysis
The Department of Health and Human Services, through the National Institutes of Health, has awarded the Mayo Clinic a $40.3M contract to continue operating the All of Us Biobank for a two-year period (2025-2027). This award expands on the existing biobank, which has collected nearly 15 million biospecimen aliquots from over 600,000 participants. The Mayo Clinic, as a private non-profit, is the direct recipient, and no publicly traded parent company or subsidiary is involved. Consequently, the contract does not directly map to any public equity. However, the contract underscores the federal government's commitment to precision medicine and large-scale biobanking, which benefits the broader healthcare and technology sectors. Companies involved in genomic sequencing, laboratory diagnostics, and data analytics may see indirect tailwinds as the program scales. No related legislation in the provided signals directly authorizes this specific award; the All of Us program was established through the Precision Medicine Initiative. Historical patterns show that sustained NIH funding for cohort studies like All of Us drives demand for laboratory equipment, consumables, and informatics services, benefiting companies such as Thermo Fisher Scientific ($TMO), Illumina ($ILMN), and Labcorp ($LH) over the long term. The absence of a direct public company recipient limits immediate stock impact, but the sector-wide implications are positive.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
MAYO CLINIC: $32.4M Department of Health and Human Services Federal Award
FOUNDATION MEDICINE, INC.: $22.0M Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restriction on Entry of Certain Nonimmigrant Workers
This proclamation extends for an additional 12 months the existing restriction on entry of H-1B nonimmigrant workers, which requires a $100,000 payment per petition (with limited exceptions) and is supported by a DHS weighted selection process that prioritizes higher-skilled, higher-paid workers. The action continues to target IT staffing and outsourcing firms that have abused the program, and it maintains the requirement for ongoing rulemakings by DHS and DOL to further reform wage protections and program integrity.
RESTORING AMERICAN SALTWATER ANGLING AND RECREATION
This executive order directs federal agencies (primarily NOAA and the Department of Commerce) to shift fisheries management toward prioritizing recreational fishing over commercial interests by modernizing data collection, replacing outdated mail-in surveys with real-time mobile reporting, and allowing state-collected data to substitute for federal data when error rates are lower. It also mandates reviewing and potentially revising National Standards under the Magnuson-Stevens Act, rescinding regulations that restrict marine access, and launching pilot programs for iconic fisheries like Atlantic striped bass, with the goal of boosting the $1.2 trillion outdoor recreation sector.
Contract Details
Recipient
MAYO CLINIC
Award Amount
$40,318,164
Awarding Agency
Department of Health and Human Services
Sub-Agency
National Institutes of Health
Contract Type
DIRECT PAYMENT FOR SPECIFIED USE, AS A SUBSIDY OR OTHER NON-REIMBURSABLE DIRECT FINANCIAL AID (C)
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →